SEC Form 4 · accession 0001179110-16-029578
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christophe Couturier
Officer — Chief Financial Officer
Period of report
Sep 8, 2016
Accepted (ET)
Sep 12, 2016 · 7:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 8, 2016 | A | 50,000 | $0.00 | A | 50,600 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.15 | Sep 8, 2016 | A | 200,000 | A | — | Sep 8, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents the right to receive one share of common stock upon vesting. The RSU vests as to 25% of the shares on September 6, 2017 and as to an additional 6.25% of the shares each successive three-month period thereafter, until September 6, 2020.
- F2Represents 600 shares of common stock and 50,000 RSUs.
- F3The option vests as to 25% of the option shares on September 6, 2017 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.